Granata Bio is a Boston-based biopharmaceutical company building a portfolio of fertility and reproductive-health therapies. Founded in 2018, it in-licenses and develops medications used in IVF outside the US, runs its own clinical programs, and is expanding into ovarian biology. Its lead asset is an investigational human menopausal gonadotropin in the pivotal Phase III GRACE study, and its 2025 acquisition of Oviva Therapeutics added a first-in-class therapeutic aimed at extending ovarian function. The company targets the multi-billion-dollar global infertility medication market with the goal of expanding patient access and improving IVF outcomes.
Alife Health is a San Francisco-based health technology company building AI-powered software for IVF clinics. Its platform helps embryologists grade embryos, helps reproductive endocrinologists time ovarian stimulation, and helps clinics streamline scheduling and patient communication - all aimed at improving outcomes and lowering the cost of fertility care.
Paxton Maeder-York is the founder of Alife Health, an AI platform for IVF clinics that has raised $31.5M and raised the standard for data-driven fertility care. A Harvard-trained biomedical engineer and MBA, he previously helped build surgical robotics at Auris Health (acquired by J&J for $3.4B) and worked in product at Google X. In 2020, driven in part by the fact that his younger brother is an IVF baby, he founded Alife to apply machine learning to embryo selection, hormone dosing, and lab scheduling. By 2024 the company had launched five products, earned recognition from Fast Company and the World Economic Forum, and achieved a leadership transition - Paxton stepping into a board role as Melissa Teran took the CEO seat.